-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The optimal pre-transplant condition for anaemia (AA) is still unclear.
we conducted a forward-looking study of allogeneic transplantation from blood-related or non-blood-related confessions in adult AA patients.
we assessed whether reduced doses of cyclophosphamide (CY) reduced toxicity while maintaining the transplant, and whether low doses of thymoglobulin safely prevented graft anti-host disease (GVHD).
pre-treatment options include fluorodalabin 120 mg/m2, CY 100 mg/kg, thymus globulin 2.5 mg/kg, with or without 2 Gy systemic exposure.
analyzed 27 patients with a medium age of 36.
, 16 patients received transplants from relative donors.
stem cells in 26 patients were sourced from bone marrow.
all but one patient who died prematurely had a neutral granulocyte transplant at 19 days in the mid-stage.
6 and 5 patients were observed at 30 and 90 days, respectively.
only one patient experienced a secondary transplant failure that was fully inline with the body type.
none of the patients had severe acute GVHD.
37.7% of chronic GVHD in the first year of the year.
survival rate was 96.3 per cent for the first and third years of the year.
1 patient detected a high EB virus-DNA load at 60 days.
had EBV-lymphatic growth in one year.
, the results show that the condition scheme in this study is safe and effective.
but the rate of chronic GVHD is relatively high and needs further improvement.
.
